Please login to the form below

Not currently logged in
Email:
Password:

ankylosing spondylitis

This page shows the latest ankylosing spondylitis news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Cosentyx misses the mark in Humira head-to-head

Novartis’ Cosentyx misses the mark in Humira head-to-head

The interleukin-17 inhibitor is already approved for another form of the disease, ankylosing spondylitis.

Latest news

More from news
Approximately 5 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    The two infliximab biosimilars are also included in the cost-effectiveness watchdog's ongoing appraisals of TNF-alpha inhibitors for ankylosing spondylitis and its review of Humira, Enbrel, Remicade, Cimzia, Simponi,

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    Emerging area. Marketed in 2007. RA = rheumatoid arthritis; AS = ankylosing spondylitis; CD = Crohn's disease; PA = psoriatic arthritis; PS = psoriasis;  . UC = ulcerative colitis; NHL = non-Hodgkin lymphoma; PCI = percutaneous coronary intervention

  • Gaming tackles back pain

    Built on a strong, simple strategy it used multiple channels to flood the world of men aged 18-40 with symptoms of Ankylosing Spondylitis (AS), a progressive, debilitating condition. ... With a barely pronounceable name, frequent confusion with common

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics